Correlation Between Takeda Pharmaceutical and Sangamo Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Takeda Pharmaceutical and Sangamo Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Takeda Pharmaceutical and Sangamo Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Takeda Pharmaceutical Co and Sangamo Therapeutics, you can compare the effects of market volatilities on Takeda Pharmaceutical and Sangamo Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Takeda Pharmaceutical with a short position of Sangamo Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Takeda Pharmaceutical and Sangamo Therapeutics.

Diversification Opportunities for Takeda Pharmaceutical and Sangamo Therapeutics

-0.83
  Correlation Coefficient

Pay attention - limited upside

The 3 months correlation between Takeda and Sangamo is -0.83. Overlapping area represents the amount of risk that can be diversified away by holding Takeda Pharmaceutical Co and Sangamo Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Sangamo Therapeutics and Takeda Pharmaceutical is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Takeda Pharmaceutical Co are associated (or correlated) with Sangamo Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Sangamo Therapeutics has no effect on the direction of Takeda Pharmaceutical i.e., Takeda Pharmaceutical and Sangamo Therapeutics go up and down completely randomly.

Pair Corralation between Takeda Pharmaceutical and Sangamo Therapeutics

Considering the 90-day investment horizon Takeda Pharmaceutical Co is expected to under-perform the Sangamo Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Takeda Pharmaceutical Co is 7.81 times less risky than Sangamo Therapeutics. The stock trades about -0.03 of its potential returns per unit of risk. The Sangamo Therapeutics is currently generating about 0.06 of returns per unit of risk over similar time horizon. If you would invest  128.00  in Sangamo Therapeutics on August 31, 2024 and sell it today you would earn a total of  102.00  from holding Sangamo Therapeutics or generate 79.69% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthSignificant
Accuracy100.0%
ValuesDaily Returns

Takeda Pharmaceutical Co  vs.  Sangamo Therapeutics

 Performance 
       Timeline  
Takeda Pharmaceutical 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Takeda Pharmaceutical Co has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unsteady performance, the Stock's basic indicators remain persistent and the latest mess on Wall Street may also be a sign of long-standing gains for the company institutional investors.
Sangamo Therapeutics 

Risk-Adjusted Performance

16 of 100

 
Weak
 
Strong
Solid
Compared to the overall equity markets, risk-adjusted returns on investments in Sangamo Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain primary indicators, Sangamo Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point.

Takeda Pharmaceutical and Sangamo Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Takeda Pharmaceutical and Sangamo Therapeutics

The main advantage of trading using opposite Takeda Pharmaceutical and Sangamo Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Takeda Pharmaceutical position performs unexpectedly, Sangamo Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Sangamo Therapeutics will offset losses from the drop in Sangamo Therapeutics' long position.
The idea behind Takeda Pharmaceutical Co and Sangamo Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance